Hepatocellular Carcinoma
Conditions
Keywords
Oncoxin, Safety of Oncoxin, Therapeutic efficacy of Oncoxin, Improvement of quality of life with Oncoxin, Survival benefit with Oncoxin
Brief summary
Oncoxin is safe and results in improved survival in patients with hepatocellular carcinoma
Detailed description
To assess therapeutic efficacy and safety of Oncoxin in hepatocellular carcinoma To see if there is reduction in serum alpha fetoprotein level in hepatocellular carcinoma patients after administration of Oncoxin To see if there is reduction tumor size and or number in hepatocellular carcinoma patients after administration of Oncoxin To see if there is improvement of quality of life in hepatocellular carcinoma patients after administration of Oncoxin To see if there is improved survival in hepatocellular carcinoma patients after administration of oncoxin
Interventions
DIETARY_SUPPLEMENTOncoxin
20 patients with hepatocellular carcinoma will receive syrup Oncoxin 25 ml bd and capsule Oncoxin 1 cap bd for 24 weeks
OTHERSupportive treatment
patients will receive only supportive treatment. No chemotherapy, radiotherapy, tumor ablation or surgery will be performed
Sponsors
Clinical Research Organization, Dhaka, Bangladesh
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Patients with HCC irrespective of etiology, age, gender and status of underlying liver disease. * Patients with HCC who are not suitable candidates for established modalities of treatment i.e. surgery and/or chemotherapy. * Patients with HCC who have evidence of tumor metastasis * Patients with HCC who are voluntarily unwilling to take established modalities of treatment i.e. surgery and/or chemotherapy. * Patients with HCC in whom all possible treatment options have been exhausted.
Exclusion criteria
* Patients with HCC who are suitable candidates for established modalities of treatment i.e. surgery and/or chemotherapy. * Patients with HCC who have no evidence of tumor metastasis * Patients with HCC who are willing to take established modalities of treatment i.e. surgery and/or chemotherapy. * Patients with HCC who are voluntarily unwilling to be included in the trial
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of patients who have prolonged survival after receiving Oncoxin | 48 weeks | To study the number of participants who have prolonged survival after receiving Oncoxin for 24 weeks. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Reduction in serum alpha-fetoprotein level and decrease in tumor size | 48 weeks | To see whether Oncoxin results in reduction in serum alpha-fetoprotein level and decrease in tumor size in hepatocellular carcinoma patients off treatment for 24 weeks, after receiving Oncoxin for 24 weeks. |
Countries
Bangladesh
Outcome results
None listed